Evan Y Yu

23PUBLICATIONS

262CO-AUTHORS

Predictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)Cancer geneticsMolecular targetsRadiation therapy

Get your video featured.

Publish with JoVE

Get your video featured.

Publish with JoVE

Publications (23)

Sort by Publication Date:

|May 26, 2026

Integrative Surface Antigen Profiling of KLK2 and STEAP1 in Advanced Prostate Cancer.

|Mar 31, 2026

PSMA PET/CT-derived Tumor Volume for Predicting Outcomes in Patients with Metastatic Castration-Resistant Prostate Cancer Receiving <sup>177</sup>Lu-PSMA-617.

Alireza Ghodsi, Lukas Owens, Ridvan Arda Demirci

|Mar 04, 2026

131I-LNTH-1095 Radioligand Therapy plus Enzalutamide versus Enzalutamide Alone in Men with PSMA-Avid Metastatic Castration-Resistant Prostate Cancer: A Phase II Study.

Evan Y Yu, Vivek Narayan, Giuseppe Esposito

|Feb 26, 2026

Trial Design and Objectives for Patients With Prostate Cancer: Recommendations From the Prostate Cancer Working Group 4.

Andrew J Armstrong, Michael J Morris, Wassim Abida

|Feb 24, 2026

Steroidogenesis inhibitor opevesostat (MK-5684) for metastatic castration-resistant prostate cancer: OMAHA-003 and OMAHA-004 trial designs.

Evan Y Yu, Christian Gratzke, Mauricio Burotto

|Nov 02, 2025

DARolutamide ObservationaL (DAROL) study in patients with nonmetastatic castration-resistant prostate cancer: prespecified third interim analysis.

Evan Y Yu, Hiroyoshi Suzuki, Christopher M Pieczonka

Pageof 4

Frequent Collaborators

Heather H Cheng

Peter S Nelson

Roman Gulati

Michael T Schweizer

Robert B Montgomery

Petros Grivas

Ruben Raychaudhuri

Thomas Hope

Todd Yezefski

Andrew Hsieh

Frequent Collaborators

Heather H Cheng

Peter S Nelson

Roman Gulati

Michael T Schweizer